Free Trial

UnitedHealth Group (UNH) Stock Forecast & Price Target

UnitedHealth Group logo
$586.23 -13.24 (-2.21%)
Closing price 04/14/2025 03:58 PM Eastern
Extended Trading
$586.55 +0.32 (+0.05%)
As of 09:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
22

Based on 22 Wall Street analysts who have issued ratings for UnitedHealth Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 22 analysts, 20 have given a buy rating, and 2 have given a strong buy rating for UNH.

Consensus Price Target

$632.85
7.95% Upside
According to the 22 analysts' twelve-month price targets for UnitedHealth Group, the average price target is $632.85. The highest price target for UNH is $700.00, while the lowest price target for UNH is $559.00. The average price target represents a forecasted upside of 7.95% from the current price of $586.23.
Get the Latest News and Ratings for UNH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for UnitedHealth Group and its competitors.

Sign Up

UNH Analyst Ratings Over Time

TypeCurrent Forecast
4/15/24 to 4/15/25
1 Month Ago
3/16/24 to 3/16/25
3 Months Ago
1/16/24 to 1/15/25
1 Year Ago
4/16/23 to 4/15/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
3 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
20 Buy rating(s)
19 Buy rating(s)
18 Buy rating(s)
15 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$632.85$629.32$626.79$573.80
Forecasted Upside7.95% Upside28.82% Upside15.39% Upside28.76% Upside
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Remove Ads

UNH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

UNH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

UnitedHealth Group Stock vs. The Competition

TypeUnitedHealth GroupMedical CompaniesS&P 500
Consensus Rating Score
3.09
2.82
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside7.95% Upside24,954.71% Upside25.80% Upside
News Sentiment Rating
Positive News

See Recent UNH News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/11/2025Truist Financial
2 of 5 stars
David Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$610.00 ➝ $660.00+10.91%
4/9/2025Mizuho
3 of 5 stars
Ann Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$600.00 ➝ $650.00+17.37%
1/28/2025Wells Fargo & Company
3 of 5 stars
Stephen Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$694.00 ➝ $660.00+21.46%
1/17/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$655.00 ➝ $642.00+24.45%
1/17/2025KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Gillmor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$650.00 ➝ $650.00+25.39%
1/17/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sarah James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$700.00 ➝ $700.00+36.71%
1/10/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
1/10/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$595.00+11.26%
1/2/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$605.00 ➝ $600.00+18.61%
12/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$610.00 ➝ $640.00+14.74%
12/5/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$605.00 ➝ $675.00+10.54%
12/3/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$595.00 ➝ $625.00+2.72%
10/18/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$601.00 ➝ $609.00+7.84%
10/16/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$680.00 ➝ $650.00+13.16%
10/16/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$615.00 ➝ $595.00+7.31%
10/16/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$675.00 ➝ $650.00+17.23%
10/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$615.00 ➝ $610.00+10.02%
7/17/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$570.00 ➝ $600.00+4.95%
7/17/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$597.00 ➝ $640.00+16.60%
7/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$481.00 ➝ $647.00+17.88%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$546.00 ➝ $559.00+15.75%
3/13/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
7/18/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$595.00 ➝ $603.00+24.55%
6/14/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$625.00 ➝ $560.00+13.98%
4/17/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$590.00 ➝ $600.00+17.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:20 AM ET.


Should I Buy UnitedHealth Group Stock? UNH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 8, 2025. Please send any questions or comments about these UnitedHealth Group pros and cons to contact@marketbeat.com.

UnitedHealth Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in UnitedHealth Group:

  • UnitedHealth Group is expected to post earnings per share of 29.54 for the current year, indicating strong profitability and growth potential.
  • The company recently declared a quarterly dividend of $2.10 per share, which translates to an annualized dividend of $8.40 and a yield of 1.60%. This consistent dividend payment can provide a steady income stream for investors.
  • Insider buying activity has been noted, with a director purchasing 1,000 shares at an average cost of $511.57 per share. This suggests confidence in the company's future performance, as insiders typically have a better understanding of the company's prospects.
  • UnitedHealth Group operates through four segments, including UnitedHealthcare and Optum, which diversifies its revenue streams and reduces risk associated with reliance on a single business line.
  • The company's dividend payout ratio is currently 54.19%, indicating a balanced approach to returning profits to shareholders while still reinvesting in growth opportunities.

UnitedHealth Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in UnitedHealth Group for these reasons:

  • Despite the positive outlook, the stock price may be perceived as high, which could deter value-focused investors looking for bargains.
  • Corporate insiders own only 0.33% of the company's stock, which may raise concerns about alignment between management and shareholder interests.
  • The healthcare sector is subject to regulatory changes and uncertainties, which can impact profitability and operational stability.
  • Market volatility can affect stock performance, and as a large healthcare provider, UnitedHealth Group may be sensitive to economic downturns that impact consumer spending on health services.
  • While the dividend is attractive, a payout ratio of 54.19% suggests that over half of earnings are distributed to shareholders, which could limit funds available for reinvestment in growth initiatives.

UNH Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for UnitedHealth Group is $632.85, with a high forecast of $700.00 and a low forecast of $559.00.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UnitedHealth Group in the last twelve months. There are currently 20 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UNH shares.

According to analysts, UnitedHealth Group's stock has a predicted upside of 7.95% based on their 12-month stock forecasts.

UnitedHealth Group has been rated by research analysts at Barclays, Cantor Fitzgerald, KeyCorp, Mizuho, Truist Financial, and Wells Fargo & Company in the past 90 days.

Analysts like UnitedHealth Group more than other "medical" companies. The consensus rating for UnitedHealth Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how UNH compares to other companies.


This page (NYSE:UNH) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners